Scynexis Inc. followed up its Phase III success for ibrexafungerp in vulvovaginal candidiasis (VVC) last November with a second pivotal study hitting all endpoints. Now, the New Jersey biotech plans to file a new drug application for the first-in-class triterpenoid antifungal with continuing trials aimed at label expansions.
In topline data from the VANISH-306 study released 21 April, 63.3% of 188 modified intent-to-treat patients (p value ≤0.01) achieved...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://insights.citeline.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)